Importer of Controlled Substances; Notice of Application, 7923-7924 [E9-3650]

Download as PDF Federal Register / Vol. 74, No. 33 / Friday, February 20, 2009 / Notices EIR. The Draft EIS/EIR describes and presents the environmental effects of the No-Action Alternative and four action alternatives. Five public hearings will be held to receive comments from individuals and organizations on the Draft EIS/EIR. DATES: Five public hearings have been scheduled to receive oral or written comments regarding environmental effects: • Monday, March 23, 2009, 1:30 p.m.–3:30 p.m., Sacramento, CA. • Tuesday, March 24, 2009, 6:30 p.m.–8:30 p.m., Livermore, CA. • Thursday, March 26, 2009, 6:30 p.m.–8:30 p.m., Dublin, CA. • Tuesday, March 31, 2009, 6:30 p.m.–8:30 p.m., Concord, CA. • Thursday, April 2, 2009, 6:30 p.m.– 8:30 p.m., Oakley, CA. A 1-hour open house to view project information and interact with the project team will precede the public hearings. The Draft EIS/EIR will be available for a 60-day public review period. Comments are due by April 21, 2009. ADDRESSES: The public hearings will be held at the following locations: • Sacramento at the Bonderson Building Hearing Room 102A/B, 901 P St. • Livermore at Zone 7 Water Agency Board Room, 100 North Canyons Parkway. • Dublin at the San Ramon Services District Board Room, 7051 Dublin Blvd. • Concord at the Heald College and Conference Center, 5130 Commercial Circle. • Oakley at the Ironhouse Elementary Multi-purpose Room, 4801 Frank Hengel Way. Send written comments on the Draft EIS/EIR to Mr. Louis Moore, Bureau of Reclamation, 2800 Cottage Way, Sacramento, CA 95825. Copies of the Draft EIS/EIR may be requested from Ms. Marguerite Naillon, Project Manager, CCWD, at 925–688– 8018 or lvstudies@hotmail.com. The Draft EIS/EIR is also accessible from the following Web site: https:// www.usbr.gov/mp/nepa/ nepa_projdetails.cfm?Project_ID=903 . See SUPPLEMENTARY INFORMATION Section for locations where copies of the Draft EIS/EIR are available for public review. FOR FURTHER INFORMATION CONTACT: Mr. Louis Moore, Bureau of Reclamation, at 916–978–5189 (TDD 916–978–5608), or wmoore@mp.usbr.gov. SUPPLEMENTARY INFORMATION: The Draft EIS/EIR documents the direct, indirect, and cumulative effects to the physical, biological, and socioeconomic VerDate Nov<24>2008 17:55 Feb 19, 2009 Jkt 217001 environment that may result from the expansion of Los Vaqueros Reservoir. The Los Vaqueros Reservoir Expansion Project Draft EIS/EIR evaluates expanding the existing Los Vaqueros Reservoir and conveyance facilities. The project objectives consist of: (1) Developing water supplies for environmental water management that supports fish protection, habitat management, and other environmental water needs; (2) increasing water supply reliability for water providers within the San Francisco Bay Area, to help meet municipal and industrial water demands during drought periods and emergencies or to address shortages due to regulatory and environmental restrictions; and (3) improving the quality of water deliveries to municipal and industrial customers in the San Francisco Bay Area, without impairing the project’s ability to meet the environmental and water supply reliability objectives stated above. One of the five potential surface storage projects described in the CALFED Bay-Delta Program’s long-term plan is the expansion of the existing Los Vaqueros Reservoir, an existing 100,000 acre-foot off-stream surface storage facility, located in Contra Costa County, California. The existing facility is owned and operated by the CCWD. The primary study area includes the Los Vaqueros Reservoir watershed and associated dam and reservoir facilities, which are situated in the coastal foothills west of the Delta and east of the Bay Area, the central and south Delta, and service areas of Bay Area water agencies. The Bay Area water agencies affected include CCWD, Alameda County Water District, Santa Clara Valley Water District, and Alameda County Flood Control and Water Conservation District—Zone 7. Due to the project influence on other programs and projects, an extended study area is defined to include the service areas of the San Francisco Public Utility Commission and the Central Valley of California. Reclamation was authorized in Public Law 108–7 (Omnibus Appropriations Act of 2003) to conduct a feasibilitylevel investigation of the potential expansion of Los Vaqueros Reservoir. Planning studies have focused on identifying water resources problems, needs, and opportunities in the primary study area; developing a set of planning objectives; and formulating alternatives. Copies of the Draft EIS/EIR are available for public review at the following locations: • Bureau of Reclamation, Mid-Pacific Region, Regional Library, 2800 Cottage Way, Sacramento, CA 95825. PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 7923 • Contra Costa Water District 1331 Concord Avenue, Concord, CA 94520. • California Bay-Delta Authority, 650 Capitol Mall, 5th Floor, Sacramento, CA 95814. • Bureau of Reclamation, Denver Office Library, Building 67, Room 167, Denver Federal Center, 6th and Kipling, Denver, CO 80225. • Natural Resources Library, U.S. Department of the Interior, 1849 C Street, NW., Main Interior Building, Washington, DC 20240–0001. If special assistance is required at the public hearings, please contact Mr. Louis Moore at 916–978–5189, or via email at wmoore@mp.usbr.gov. Please notify Mr. Moore as far in advance as possible to enable Reclamation to secure the needed services. If a request cannot be honored, the requestor will be notified. A telephone device for the hearing impaired (TDD) is available at 916–978–5608. Before including your name, address, phone number, e-mail address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. Dated: February 11, 2009. Richard M. Johnson, Acting Regional Director, Mid-Pacific Region. [FR Doc. E9–3653 Filed 2–19–09; 8:45 am] BILLING CODE 4310–MN–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on January 16, 2009, Supernus Pharmaceuticals, Inc., 1550 East Gude Drive, Rockville, Maryland 20850, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as E:\FR\FM\20FEN1.SGM 20FEN1 7924 Federal Register / Vol. 74, No. 33 / Friday, February 20, 2009 / Notices an importer of the basic classes of controlled substances listed in schedule II: Drug Schedule Oxycodone (9143) ......................... Morphine (9300) ............................ II II Drug The company plans to import controlled substances for clinical trials and analytical testing. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 23, 2009. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: February 13, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–3650 Filed 2–19–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 8, 2009, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, VerDate Nov<24>2008 17:55 Feb 19, 2009 Jkt 217001 Massachusetts 01760–2447, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Schedule Cathinone (1235) .......................... Methcathinone (1237) ................... Aminorex (1585) ............................ Gamma Hydroxybutyric Acid (2010). Alpha-ethyltryptamine (7249) ........ Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ...... 4–Bromo-2,5dimethoxyamphetamine (7391). 4–Bromo-2,5dimethoxyphenethylamine (7392). 2,5–Dimethoxyamphetamine (7396). 3,4–Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4–Methylenedioxy-Nethylamphetamine (7404). 3,4– Methylenedioxymethamphetamine (MDMA) (7405). Psilocybin (7437) ........................... 5–Methoxy-N,Ndiisopropyltryptamine (7439). 1-[1-(2– Thienyl)cyclohexyl]piperidine (TCP) (7470). 1–Benzylpiperazine (BZP) (7493) Heroin (9200) ................................ Normorphine (9313) ...................... Amphetamine (1100) ..................... Methamphetamine (1105) ............. Nabilone (7379) ............................. 1–Phenylcyclohexylamine (7460) Phencyclidine (7471) ..................... Cocaine (9041) .............................. Codeine (9050) ............................. Diprenorphine (9058) .................... Ecgonine (9180) ............................ Levomethorphan (9210) ................ Levorphanol (9220) ....................... Meperidine (9230) ......................... Metazocine (9240) ........................ Methadone (9250) ......................... Morphine (9300) ............................ Thebaine (9333) ............................ Levo-alphacetylmethadol (9648) ... Carfentanil (9743) ......................... Fentanyl (9801) ............................. I I I I I I I I Frm 00075 Fmt 4703 Sfmt 4703 Dated: February 13, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–3646 Filed 2–19–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration I Manufacturer of Controlled Substances; Notice of Registration I By Notice dated October 28, 2008 and published in the Federal Register on November 3, 2008, (73 FR 65404), Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: I I I I I I I I I I II II II II II II II II II II II II II II II II II II II The company plans to manufacture reference standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement PO 00000 Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 21, 2009. Drug Tetrahydrocannabinols (7370) ...... Dihydromorphine (9145) ............... Dihydrocodeine (9120) .................. Oxycodone (9143) ......................... Hydromorphone (9150) ................. Hydrocodone (9193) ..................... Remifentanil (9739) ....................... Sufentanil (9740) ........................... Fentanyl (9801) ............................. Schedule I I II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted E:\FR\FM\20FEN1.SGM 20FEN1

Agencies

[Federal Register Volume 74, Number 33 (Friday, February 20, 2009)]
[Notices]
[Pages 7923-7924]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-3650]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in schedule I or II, and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
(CFR), 1301.34(a), this is notice that on January 16, 2009, Supernus 
Pharmaceuticals, Inc., 1550 East Gude Drive, Rockville, Maryland 20850, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as

[[Page 7924]]

an importer of the basic classes of controlled substances listed in 
schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Oxycodone (9143)............................  II
Morphine (9300).............................  II
------------------------------------------------------------------------

    The company plans to import controlled substances for clinical 
trials and analytical testing.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than March 23, 2009.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745-46), all 
applicants for registration to import a basic class of any controlled 
substances in schedule I or II are, and will continue to be, required 
to demonstrate to the Deputy Assistant Administrator, Office of 
Diversion Control, Drug Enforcement Administration, that the 
requirements for such registration pursuant to 21 U.S.C. 958(a); 21 
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are 
satisfied.

    Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-3650 Filed 2-19-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.